Tofacitinib as a Rescue Therapy for Ulcerative Colitis in Pregnancy
Catherine Rowan, Fiona Yeaman, Kenneth Ernest-Suárez, Marie‐Louise Martin, Remo Panaccione, Tushar Shukla, Matt Grossi, Meghan Vlasschaert, Kerri L. Novak, Cynthia H. Seow
Abstract
Lay Summary Tofacitinib, a potentially teratogenic nonselective Janus Kinase inhibitor was used as salvage therapy for ulcerative colitis during pregnancy with corticosteroids, maintenance ustekinumab, and rectal 5-ASA therapy. Corticosteroid-free remission ensued, resulting in term delivery without congenital malformations and avoidance of colectomy.
Topics & Concepts
TofacitinibUlcerative colitisMedicineUstekinumabPregnancyRescue therapyColectomyMaintenance therapyJanus kinase inhibitorInflammatory bowel diseaseSalvage therapyGastroenterologyInternal medicineSurgeryAdalimumabChemotherapyDiseaseGeneticsRheumatoid arthritisBiologyPregnancy and Medication ImpactEosinophilic EsophagitisReproductive System and Pregnancy